Semafore Pharmaceuticals, Inc. Announces Issuance of U.S. Patent Covering Method of Use for PI3K Inhibitors
6/29/2010 10:25:51 AM
INDIANAPOLIS--(BUSINESS WIRE)--Semafore Pharmaceuticals today announced the United States Patent and Trademark Office (PTO) has issued United States Patent Number 7,745,485 entitled “Compositions and methods for identifying agents which modulate PTEN function and PI-3 kinase pathways.” This patent covers methods of inhibiting the spread of cancer in patients using phosphoinositide-3-kinase (PI3K) inhibitors alone or in combination with chemotherapeutic agents.
comments powered by